Use access key #2 to skip to page content.
  • S&P 500: 1,070.52
  • Change: 1.30%
$5.39 -0.04 (-0.74%)
2/9/2010 4:00 PM

Geron Corp (GERN)

CAPS Rating:
***

A biopharmaceutical company which is developing first-in-class therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating GERN

Add Stock to Watchlist

What the Community Thinks

Total Members

543 Outperforms
69 Underperforms
 

All-Stars

117 Outperforms
22 Underperforms
 

Wall Street

5 Outperforms
1 Underperforms
 

Members bullish on GERN are also bullish on:

Members bearish on GERN are also bearish on:

Ticker Tags

Defensive (1457), Healthcare (711), Biotechnology (220), Micro Cap (4701), Aggressive Growth (860), Growth (1902), Rule Breakers Universe (125)
Suggest a tag

Geron Corp At A Glance

Current Price: $5.39
Last Trade Time: 2/9/2010 4:00 PM
Open: $5.50
Previous Close: $5.43
Daily Range: $5.35 - $5.54
52-Week Range: $3.67 - $9.24
Volume: 990,368
Market Cap: $493.87M
P/E Ratio: 0.00
Compare Our Special Broker Offers!

Stock Trends

GERN VS S&P 500 (SPY)

News & Discussion Boards

Top Bull Pitch

Recs

2

Geron Corp (GERN)

Avatar end2war (< 20) Submitted: 12/18/09 2:28 PM

This development stage biotech has developed a major position in two related fields, cancer drugs based on tolermerase, and regenerative medicine based on embryonic stem cell drugs. It has a large patent portfolio in both fields, and it has stage I and II trials in both areas that are advancing nice...More

Replies: 0 | Reply | Permalink

Top Bear Pitch

Recs

3

Geron Corp (GERN)

Avatar SwingCorey (40.79) Submitted: 1/11/10 10:59 AM

Embryonic stem cell research, regardless of the current presidential/congressional support, is in trouble. They have not figured out how to fix the problems (e.g. cancerous tumors), yet "adult" stem cells (e.g., from dental pulp, bone marrow, and fatty deposits) are consistently meeting or exceedin...More

Replies: 2 | Reply | Permalink

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 153 :   1 2 3 4 5 Next » Jump to page:

Show Pitch Replies

Recs

0

 (GERN)

Avatar kinosternon (33.72) Submitted: 2/03/10 1:24 PM : Underperform Start Price: $5.64 GERN Score: 1.90

Geron has gambled with embryonic stem cells. Prop. 71, which passed over 5 years ago, has been a disaster and only the scientists that received funding have benefited from it's passage. A number of other stem cell companies (Aastrom Biosciences-ASTM, Cytori Therapeutics-CYTX, and Osiris-OSIR) have and continue to move products through clinical trials and into various markets with advance coming from non-embryonic stem cells. Wall Strret has not yet realized the difference between embryonic and non-embryonic stem cells; in my opinion, that will change soon.

Report this Post Replies: 1 | Reply | Permalink

Recs

0

 (GERN)

Avatar SUPERMANSTOCKS (27.04) Submitted: 2/02/10 5:09 PM : Underperform Start Price: $5.77 GERN Score: 4.16

If you like this one you will like GENVEC (GNVC) Both claim to be out to kill cancer. Not sure if they will or not. But I see alot of hype around finding a cure and its been 37 years and I still haven't seen one yet.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (GERN)

Avatar Biotech2010 (40.47) Submitted: 1/26/10 8:52 PM : Outperform Start Price: $5.63 GERN Score: -2.48

5.97

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (GERN)

Avatar cruzit (< 20) Submitted: 1/25/10 11:12 AM : Outperform Start Price: $5.76 GERN Score: -4.07

I'm buying *right now*. Anti-cancer is just one of their high profile drugs in the pipeline. Between Geron and Lexicon there are many new discoveries coming out very soon.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (GERN)

Avatar iddqkfyou (< 20) Submitted: 1/23/10 9:32 AM : Outperform Start Price: $5.60 GERN Score: -2.08

Treatments of the future.

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 153 :   1 2 3 4 5 Next » Jump to page:

Wall Street

Results 1 - 6 of 6  

picks per page. CHANGE Expand All Pitches

Top
Pick
Member NameMember RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackRodmanRen < 20 01/23/09 Outperform NS $7.04-23.44%+34.21%-57.64
TrackMerriman < 20 12/11/08 Outperform NS $4.29+25.64%+21.57%+4.07
TrackUBS 87.99 01/29/08 Outperform NS $5.00+7.80%-17.90%+25.70
TrackEveillard 93.31 09/30/07 Outperform NS $7.32-26.37%-26.38%+0.01 Toggle the visibility of 60-Second Pitch and replies
TrackTobinSmith < 20 11/11/06 Outperform 1Y $8.59-37.25%-17.68%-19.58
TrackJimCramer < 20 03/24/06 Underperform 3W $8.33-35.29%-11.76%+23.53

Results 1 - 6 of 6  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners

EQWEBD02 78ms